Hypotensive Agents Reduce Bleeding in ESS

Diltiazem, esmolol, dexmedetomidine, labetalol, and clonidine were associated with improved surgical field quality and comparable safety profiles

By
Olivia Anderson
January 30, 2026
3 min

Conexiant

Overview

A systematic review and network meta-analysis found that various pharmacologic agents effectively reduce intraoperative bleeding during endoscopic sinus surgery (ESS). Diltiazem, esmolol, and dexmedetomidine were among the most effective agents, with tailored drug selection recommended based on surgical priorities.

Background

Endoscopic sinus surgery (ESS) is frequently performed to address chronic sinonasal conditions, where excessive bleeding can complicate procedures and increase risks. Controlled hypotension is a common strategy to enhance surgical visibility, yet the comparative effectiveness of different hypotensive agents has been unclear. This analysis provides clarity on the efficacy and safety of various agents in reducing intraoperative bleeding.

Data Highlights

{'Diltiazem': {'Bleeding Score Reduction': 'Greatest (specific value needed)', 'Mean Arterial Pressure Reduction': '-30 mm Hg'}, 'Esmolol': {'Bleeding Score Reduction': 'Significant (specific value needed)', 'Mean Arterial Pressure Reduction': 'Significant (specific value needed)'}, 'Dexmedetomidine': {'Bleeding Score Reduction': 'Significant (specific value needed)', 'Mean Arterial Pressure Reduction': 'Largest (specific value needed)'}, 'Labetalol': {'Bleeding Score Reduction': 'Significant (specific value needed)', 'Mean Arterial Pressure Reduction': 'Significant (specific value needed)'}, 'Clonidine': {'Bleeding Score Reduction': 'Significant (specific value needed)', 'Mean Arterial Pressure Reduction': 'Significant (specific value needed)'}}

Key Findings

Controlled hypotension effectively reduces intraoperative bleeding during ESS.
Diltiazem showed the greatest reduction in bleeding scores compared to placebo.
Dexmedetomidine significantly lowered mean arterial pressure by approximately 30 mm Hg.
Esmolol and labetalol were associated with shorter emergence times and recovery of consciousness.
Safety profiles were comparable across agents, with no consistent differences in adverse effects.

Clinical Implications

Clinicians should consider the specific pharmacologic agents for controlled hypotension based on individual patient characteristics and surgical goals. The findings support the use of tailored hypotensive strategies to optimize surgical conditions while maintaining hemodynamic stability.

Conclusion

This meta-analysis underscores the effectiveness of multiple hypotensive agents in reducing bleeding during ESS, advocating for a personalized approach to agent selection. Future research should focus on standardizing protocols to enhance the applicability of these findings.